Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to $775 million in additional potential milestones plus royalties on net sa

Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company’s preliminary estimates, and potentially int

Enara’s discovery of DARKFOX delivers on the vision of translating the dark genome into a new class of clinically actionable Dark Antigens and will be highlighted in an oral presentation at SITC 2025 DARKFOX demonstrates best-in-class target properties: high tumor specificity, homogeneous expression in tumors and high prevalence in significant patient populations including lung, breast and GI cancers ENA101, a first-in-class bispecific T cell engager against DARKFOX, has been developed and optim

The commercial availability of UCB’s Kygevvi in the US market is anticipated in the first quarter of 2026. Credit: T. Schneider/Shutterstock.com. The US Food and Drug Administration (FDA) has approved UCB’s Kygevvi (doxecitine and doxribtimine) to treat genetic mitochondrial disease, thymidine kinase 2 deficiency (TK2d). The approval is intended to treat the condition in adults and in children who exhibit symptoms before the age of 12. TK2d involves progressive and severe muscle weakness, known

Lilly anticipates submitting regulatory filings for orforglipron as a treatment for obesity by the end of 2025. Credit: Tada Images/Shutterstock.com. Eli Lilly and Company has outlined plans to develop a $3bn manufacturing facility in Katwijk, situated in the Leiden Bio Science Park, the Netherlands, bolstering its worldwide supply chain operations. The initiative will increase the company’s production capacity for oral medications, and the investment is subject to regulatory and local approvals

Created with Canva Dreamlab† Had Pfizer’s Freda Lewis-Hall not stepped in, SpringWorks’ rare disease treatment may never have reached patients. Pharmas can act now to help find the next Gomekli. The tragedy of rare disease is not only measured in lives lost—it’s also measured in lives that could have been saved, if only abandoned discoveries had been given another chance. Promising experimental therapies that could change or even save lives are often sidelined by companies, not because they fail

Third-quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 million As of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent for Rezdiffra providing protection into 2045 Launched Rezdiffra in Germany following European Commission approval Reports cash, cash equivalents, restricted cash and marketable securities of $1.1 billion as of Sept. 30, 2025 Company to host conference c

iStock, DenisDore Having seen Congress spend money to onshore semiconductor production, pharma groups are pushing for similar incentives for domestic drug manufacturing. In an effort to encourage companies to make generic drugs and ingredients in the U.S., President Donald Trump has signed executive orders this year on regulatory relief and supply chain resilience , and the FDA has made moves toward lowering barriers and creating incentives. While industry representatives have welcomed t

WAKIX® (pitolisant) Franchise Delivers Net Revenue of $239M in Q3 2025 (+29% YoY Growth) Record Increase in Average Number of Patients of Approximately 500 to Achieve 8,100 Average Patients in Q3 2025 Strong Cash Generation of $106M with $778M On Balance Sheet at end of Q3 2025 Pitolisant HD IND submitted; On Track to Initiate Phase 3 Trials in Narcolepsy and Idiopathic Hypersomnia in Q4 2025 Potential Best-In-Class Orexin 2 Agonist (BP1.15205) On Track to Dose First Subject in Q4 2025; Phase 1

ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeks Once-daily ZORYVE foam 0.3% is approved to treat seborrheic dermatitis in adults and adolescents 9 years of age and older WESTLAKE VILLAGE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that the American J